ArticleTranslational lung cancer research2021
Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors.
Article in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- The impact of comorbid COPD on survival outcomes in lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.Frontiers in immunology · 2025Pooled it
- Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis.Immunotherapy · 2024Pooled it
- Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Contrast-enhanced CT based radiomics for prediction of 3-year disease progression in NSCLC patients after anti-PD-1-targeted therapy.European journal of radiology open · 2026Article
- The Favorable Short-Term Efficacy of Preexisting COPD for Extensive-Stage Small-Cell Lung Cancer Receiving Immunotherapy.Cancer medicine · 2026Article
- Impact of chronic obstructive pulmonary disease on the prognosis of patients with extensive-stage small-cell lung cancer treated with chemoimmunotherapy.Translational lung cancer research · 2026Article
- The impact of neoadjuvant chemoimmunotherapy on pulmonary function in non-small cell lung cancer patients.Translational lung cancer research · 2026Article
- IL-8 drives EMT and malignant progression in chronic obstructive pulmonary disease-associated lung cancer via STAT3 signaling.Cell division · 2026Article
- Association between inhaled corticosteroids and anti-PD-1/PD-L1 efficacy in patients with NSCLC with concurrent COPD.iScience · 2026Article
- Impact of concurrent systemic and inhaled corticosteroid use on clinical outcomes in advanced lung cancer patients receiving immune checkpoint inhibitors.Respiratory research · 2026Article
- Can tissue immune states shape the risk of hyperprogressive disease?Frontiers in immunology · 2026Review
- User-centered design of a COPD care pathway for patients with cancer: a mixed-methods clinical trial protocol.Future oncology (London, England) · 2025Article
- The safety and effectiveness of immune checkpoint blockade in lung cancer with COPD: a systematic review and meta-analysis.Journal of thoracic disease · 2025Article
- Changes in prescribing patterns and access to immune checkpoint inhibitors in german lung cancer patients - a claims data analysis.BMC public health · 2025Article
- Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC.NPJ biofilms and microbiomes · 2025Article
- Enhanced immunotherapy response in lung adenocarcinoma patients with COPD: insights into tumor cells and immune microenvironment characteristics.Cell communication and signaling : CCS · 2025Article
- COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors.Scientific reports · 2025Article
- Association of cardiovascular disease and CIRS‑G and ACE‑27 comorbidity indices with pathological complete response of non‑small cell lung cancer to neoadjuvant chemoimmunotherapy.Experimental and therapeutic medicine · 2025Article
- Neoadjuvant immunology therapy in patients with non-small cell lung cancer and chronic obstructive pulmonary disease.Journal of thoracic disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe coexistence of chronic obstructive pulmonary disease (COPD) in lung cancer patients often correlates with a poor clinical outcome regardless of tumor stage, mainly due to older age, poor lung function, and complex comorbid disease. Emerging data suggest that the pathogenesis of both diseases involves aberrant immune functioning. We conducted this retrospective study to describe the impact of COPD on the clinical outcomes of lung cancer patients treated with immunotherapy and investigate the potential prognostic factors.
methodsIn total, 156 patients with advanced-stage lung cancer who received at least one administration of an anti-programmed cell death 1 (PD-1)/anti-programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitor (ICI) at any treatment line at Zhongshan Hospital Fudan University between May 2018 and December 2019 were enrolled in our study. Overall survival (OS) and progression-free survival (PFS) were analyzed according to the presence of COPD. We also evaluated the prognostic value of circulating cytokine levels for clinical outcome.
resultsWe found that the presence of COPD (both spirometry-based COPD and physician-defined COPD) was significantly associated with longer PFS (316
conclusionsCOPD was associated with better survival in advanced-stage lung cancer patients treated with ICIs. Plasma IL-8 and IL-2R levels were potential prognostic factors for clinical outcome. The nomograms represent a possibly useful tool for predicting the clinical outcomes of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.